Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SYK vs GEHC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GEHC Captures Overall Composite Edge (36.0 SELL vs 46.5 HOLD), While SYK Leads 5–1 on Growth & Valuation Pillars

GEHC Overall Winner 6-Pillar Tally: SYK 5 – 1 GEHC Matrix Metrics: SYK 5 – 5 GEHC

As of Nov 16, 2026, GE HealthCare Technologies Inc. (GEHC) captures the overall head-to-head institutional edge over Stryker Corporation (SYK) on higher Unified Composite conviction (36.0/100 SELL vs. 46.5/100 HOLD) after splitting the core matrix 5–5 (led by Valuation Multiples), while SYK wins 5–1 across the 6-pillar growth and valuation breakdown. SYK trades at $310.79 (19.0x Forward P/E, 24.0% operating margin) versus GEHC at $83.19 (15.1x Forward P/E, 13.8% operating margin).

  • Composite vs. Pillar Nuance: While SYK currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. GEHC 36.0/100 SELL), GEHC captures the overall institutional head-to-head verdict (5–5 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (13.8% vs. 24.0% operating margin) and revenue trajectory (+7.2% vs. +7.6% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SYK vs GEHC
SYK NYSE
Stryker Corporation
Surgical & Medical Instruments & Apparatus
$310.79
+0.37% 1D
Market Cap $118.9B
TTM Revenue $26.3B
Forward P/E 19.0x
Beta / 30D Vol 0.22β · 50% Vol
Unified Composite Score
46.5 / 100 HOLD
Tech 37.0 Fund 49.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.5 · SMA20: $312.55 · SMA50: $292.40
GEHC NASDAQ Head-to-Head Winner
GE HealthCare Technologies Inc. Common Stock
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$83.19
+0.2% 1D
Market Cap $37.0B
TTM Revenue $21.6B
Forward P/E 15.1x
Beta / 30D Vol 0.53β · 39% Vol
Unified Composite Score
36.0 / 100 SELL
Tech 20.0 Fund 32.0 Flow 58.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.3% over 20 days), RSI 69
RSI-14: 68.9 · SMA20: $78.24 · SMA50: $70.84

6-Pillar Scorecard Institutional Category Breakdown (SYK 5 – 1 GEHC)

Columns: Metric · SYK · GEHC
1. Valuation Multiples GEHC
Forward P/E 19.0x 15.1x
Trailing P/E 33.3x 17.3x
PEG Ratio 1.54x 2.21x
EV / Revenue 5.0x 2.1x
2. Growth & Scale SYK
Revenue Growth (YoY) +7.6% +7.2%
Earnings Growth (YoY) -11.7% +39.0%
TTM Revenue (USD) $26.3B $21.6B
Market Cap $118.9B $37.0B
3. Profitability & Quality SYK
Gross Margin 65.7% 39.3%
Operating Margin 24.0% 13.8%
Net Profit Margin 13.8% 10.0%
Return on Equity (ROE) 16.0% 20.0%
4. Balance Sheet & Cash Flow SYK
Cash Generation (TTM) $4.57B $1.89B
Cash Flow Margin 17.4% 8.7%
Net Cash / Leverage $11.7B Net Debt (0.64x D/E) $7.58B Net Debt (0.90x D/E)
Dividend Yield 1.10% 0.18%
5. Options & Positioning SYK
Options Structure Phase SURGE SURGE
Current IV / %ile 28.1% (5th %ile) 47.7% (6th %ile)
Put/Call OI Skew 0.30x (Call-Skewed) 0.38x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat SYK
OpEx & R&D Intensity 41.7% of Rev ($11.0B) 25.5% of Rev ($5.52B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Concentrated Oligopoly Moat Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SYK (5) vs GEHC (5)
Institutional Metric SYK GEHC Criterion Row Edge
Market Capitalization
Scale
$118.9B $37.0B Larger Scale SYK
Trailing P/E Ratio
Valuation
33.3x 17.3x Lower Multiple GEHC
Forward P/E Ratio
Valuation
19.0x 15.1x Lower Multiple GEHC
Revenue Growth (YoY)
Growth
+7.6% +7.2% Higher Growth SYK
Operating Margin (TTM)
Profitability
24.0% 13.8% Higher Margin SYK
Net Profit Margin
Profitability
13.8% 10.0% Higher Margin SYK
Return on Equity (ROE)
Capital Efficiency
16.0% 20.0% Higher ROE GEHC
52-Week Range Position
Momentum
36% ($267–$389) 79% ($59–$90) Stronger Trend GEHC
Beta / 30D Volatility
Risk Regime
0.22β · 50% Vol 0.53β · 39% Vol Lower Realized Risk GEHC
Unified Institutional Score
Composite Signal
46.5 / 100 (HOLD) 36.0 / 100 (SELL) Higher Composite SYK
Trailing 12M Revenue (USD)
Operating Scale
$26.3B $21.6B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
65.7% 39.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.54x PEG · 5.0x EV/Rev 2.21x PEG · 2.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$4.57B ($11.7B Net Debt (0.64x D/E)) $1.89B ($7.58B Net Debt (0.90x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GEHC +14.1 pp
SYK: +5.47% · GEHC: +19.57%
3M Horizon GEHC +20.74 pp
SYK: -6.21% · GEHC: +14.53%
6M Horizon GEHC +36.02 pp
SYK: -0.78% · GEHC: +35.24%
1Y Horizon GEHC +29.23 pp
SYK: -16.77% · GEHC: +12.46%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SYK Revenue GEHC Revenue SYK Op. Margin GEHC Op. Margin Margin Leader
FY2018 $13.6B N/A 18.7% N/A SYK
FY2019 $14.9B N/A 18.2% N/A SYK
FY2020 $14.3B N/A 15.5% N/A SYK
FY2021 $17.1B $17.6B 15.1% 15.9% GEHC
FY2022 $18.4B $18.3B 15.4% 13.8% SYK
FY2023 $20.5B $19.6B 19.0% 12.5% SYK
FY2024 $22.6B $19.7B 16.3% 13.3% SYK
FY2025 $25.1B $20.6B 19.5% 13.4% SYK

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SYK SURGE
8d in phase · OBV DISTRIBUTION
Current IV 28.1%
IV Percentile 5th %ile
Put/Call OI Skew 0.30x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact SYK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GEHC SURGE
8d in phase · OBV DISTRIBUTION
Current IV 47.7%
IV Percentile 6th %ile
Put/Call OI Skew 0.38x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact GEHC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SYK Moat Profile Concentrated Oligopoly Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $118.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment 41.7% of Rev ($11.0B)
90D Engineering Disclosures 0 Published · Surgical Robotics
GEHC Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $37.0B market capitalization and 13.8% operating margin.
OpEx & R&D Reinvestment 25.5% of Rev ($5.52B)
90D Engineering Disclosures 0 Published

Investor FAQ SYK vs GEHC Key Questions & Quantitative Answers

As of Nov 16, 2026, GE HealthCare Technologies Inc. (GEHC) captures the overall head-to-head institutional edge over Stryker Corporation (SYK) on higher Unified Composite conviction (36.0/100 SELL vs. 46.5/100 HOLD) after splitting the core matrix 5–5 (led by Valuation Multiples), while SYK wins 5–1 across the 6-pillar growth and valuation breakdown. SYK trades at $310.79 (19.0x Forward P/E, 24.0% operating margin) versus GEHC at $83.19 (15.1x Forward P/E, 13.8% operating margin). Composite vs. Pillar Nuance: While SYK currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. GEHC 36.0/100 SELL), GEHC captures the overall institutional head-to-head verdict (5–5 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (13.8% vs. 24.0% operating margin) and revenue trajectory (+7.2% vs. +7.6% YoY).

SYK leads the Growth & Scale pillar: SYK posts +7.6% YoY revenue growth and -11.7% YoY earnings growth on $26.3B TTM revenue (65.7% gross margin, 24.0% operating margin), compared with GEHC at +7.2% YoY revenue growth and +39.0% YoY earnings growth on $21.6B TTM revenue (39.3% gross margin, 13.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SYK cumulative revenue shifted +84.7% while GEHC shifted +17.2%. In operating R&D and SG&A reinvestment, SYK deploys 41.7% of Rev ($11.0B) (0 90-day corporate R&D disclosures) versus 25.5% of Rev ($5.52B) (0 disclosures) for GEHC.

GEHC screens cheaper on headline valuation multiples. SYK trades at 19.0x Forward P/E, 33.3x Trailing P/E, 1.54x PEG, and 5.0x EV/Revenue (17.4% FCF margin), whereas GEHC trades at 15.1x Forward P/E, 17.3x Trailing P/E, 2.21x PEG, and 2.1x EV/Revenue (8.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYK (16.0% ROE) versus GEHC (20.0% ROE) capital efficiency.

In options market volatility and institutional positioning, SYK carries 28.1% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.22β · 50% Vol realized risk). By comparison, GEHC carries 47.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.38x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.53β · 39% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.